# Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

> **NCT03249792** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 140 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** MK-2118 (IT)
- **DRUG:** MK-2118 (SC)
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03249792
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-20
- **Primary completion:** 2023-02-22
- **Final completion:** 2023-02-22
- **Target enrollment:** 140 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03249792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03249792, "Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03249792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*